Dianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated at Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research note issued to investors on Thursday, Marketbeat reports. The firm issued an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Dianthus Therapeutics’ FY2024 earnings at ($2.54) EPS.

Several other analysts also recently issued reports on DNTH. HC Wainwright started coverage on Dianthus Therapeutics in a report on Thursday, May 16th. They issued a buy rating and a $40.00 price target for the company. Raymond James raised their target price on Dianthus Therapeutics from $34.00 to $51.00 and gave the company an outperform rating in a report on Thursday, April 18th. Wedbush boosted their price target on Dianthus Therapeutics from $33.00 to $38.00 and gave the stock an outperform rating in a research report on Friday, May 10th. Jefferies Financial Group increased their price objective on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the company a buy rating in a research report on Friday, March 22nd. Finally, Lifesci Capital raised shares of Dianthus Therapeutics to a strong-buy rating in a research report on Tuesday, June 11th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of Buy and a consensus target price of $42.83.

Dianthus Therapeutics Price Performance

Dianthus Therapeutics stock opened at $25.88 on Thursday. Dianthus Therapeutics has a 12 month low of $6.58 and a 12 month high of $33.77. The company has a market cap of $759.58 million, a price-to-earnings ratio of -4.44 and a beta of 1.83. The stock’s 50-day moving average is $23.77 and its 200-day moving average is $21.65.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.11). The business had revenue of $0.87 million for the quarter, compared to analysts’ expectations of $0.48 million. Research analysts anticipate that Dianthus Therapeutics will post -2.18 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC bought a new stake in shares of Dianthus Therapeutics in the 4th quarter worth about $25,000. Citigroup Inc. acquired a new position in Dianthus Therapeutics in the third quarter worth about $53,000. Acadian Asset Management LLC bought a new stake in Dianthus Therapeutics in the third quarter valued at about $303,000. Virtu Financial LLC bought a new stake in Dianthus Therapeutics in the first quarter valued at about $390,000. Finally, Laurion Capital Management LP acquired a new stake in Dianthus Therapeutics during the third quarter valued at approximately $497,000. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.